Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308395462> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W4308395462 abstract "<h3>Background</h3> Antibiotics (ATB) induce intestinal dysbiosis and decrease the efficacy of immune checkpoint inhibitors (ICI).<sup>1,2</sup> DAV132 is an orally administered colon-targeted ATB adsorbent designed to prevent ATB-induced dysbiosis.<sup>3</sup> We investigated whether DAV132 co-administered with ATB could protect gut microbiota diversity and composition. Moreover, in murine avatar tumor model, we assessed anti-PD-1 efficacy through fecal microbiota transplantation (FMT) in germ-free (GF) or antibiotic-treated specific pathogen-free (SPF) mice. <h3>Methods</h3> Twenty-four human healthy volunteers (HV) were randomized to receive either ceftazidime-avibactam (CZA, 2g/0.5g q8h IV for 5 days) or CZA+DAV132 (12g PO tid for 7 days). CZA plasmatic and fecal pharmacodynamic levels were measured using HPLC-MS/MS. Microbiome was profiled with 16S and shotgun metagenomics at different timepoints. FMT in GF or ATB-treated SPF mice was performed using fecal samples from 3 HV and 2 HV respectively, in each group before (D1) or after 6 days (D6) of CZA+/-DAV132; subsequently mice were inoculated with MCA-205 tumor and treated intraperitoneally with anti-PD-1, 4 times every 3 days. Immunological population of tumor infiltrating lymphocytes were analyzed by flow cytometry. <h3>Results</h3> DAV132 did not impact plasmatic CZA concentrations, but significantly reduced ceftazidime concentration in feces compared to HV treated with CZA alone (p<0.001). DAV132 significantly prevented the reduction in microbiota alpha-diversity at D6 (p=0.0019) and was associated with a more rapid return to baseline microbiota composition (figure 1). Significantly more bacteria associated with better response to ICI were preserved in the DAV group compared to CZA, among which<i> Faecalibacterium praunistzii and</i> several<i> Alistipes spp</i>. FMT in GF mice transplanted with feces collected at D1 exhibited a significant anti-PD-1 activity. This anti-tumor response was inhibited in mice transplanted with D6 feces from any of the 3 CZA-treated HV. Conversely, the anti-tumor response was maintained in mice transplanted with D6 feces from any of the 3 HV treated with CZA + DAV132 (figure 2). Similar results were observed upon FMT using samples from HVs into ATB-treated SPF mice. Flow cytometry on tumor T cell infiltrates demonstrated that CZA decreased CD8<sup>+</sup>T cell infiltration and CD8<sup>+</sup>/Tregulatory ratio, compared to CZA + DAV132 treated HVs (figure 3). <h3>Conclusions</h3> DAV132 strongly prevented CZA-induced dysbiosis in HV without influencing plasmatic concentrations. In avatar mice FMT from HV treated with CZA+DAV132 was able to preserve anti-PD-1 cancer efficacy. These results provide rationale to launch clinical trials combining DAV132 in patients on ATB amenable to ICI. <h3>Acknowledgements</h3> This work was funded by Da Volterra, a French biotech company, through the sharing of fecal samples and a collaboration agreement with Pr. Routy’s lab. <h3>References</h3> Derosa L, Routy B, Desilets A, Daillère R, Terrisse S, Kroemer G, Zitvogel L. Microbiota-centered interventions: the next breakthrough in Immuno-Oncology? <i>Cancer Discov</i>. 2021;<b>11</b>(10):2396–2412. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. <i>Science</i>. 2018;<b>359</b>(6371):91–97. Vehreschild MJGT, Ducher A, Louie T, Cornely OA, Feger C, Dane A, Varastet M, Vitry F, de Gunzburg J, Andremont A, Mentré F, Wilcox MH. An open randomized multicenter Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones. <i>J Antimicrob Chemother.</i> 2022;<b>77</b>(4):1155–1165. <h3>Ethics Approval</h3> All animal studies were approved by the Institutional Animal Care Committee (CIPA) and carried out in compliance with the Canadian Council on Animal Care guidelines (Ethics numbers: C18029BRs)." @default.
- W4308395462 created "2022-11-11" @default.
- W4308395462 creator A5002443518 @default.
- W4308395462 creator A5029334249 @default.
- W4308395462 creator A5029510428 @default.
- W4308395462 creator A5039840041 @default.
- W4308395462 creator A5049738219 @default.
- W4308395462 creator A5056642071 @default.
- W4308395462 creator A5061180419 @default.
- W4308395462 creator A5068979537 @default.
- W4308395462 creator A5071981681 @default.
- W4308395462 creator A5077537859 @default.
- W4308395462 creator A5080933448 @default.
- W4308395462 date "2022-11-01" @default.
- W4308395462 modified "2023-10-18" @default.
- W4308395462 title "1306 Prevention of antibiotic-induced dysbiosis in human volunteers by DAV132 and preservation of responsiveness to anti-PD-1 therapy demonstrated by transplantation of human feces into tumor-bearing mice" @default.
- W4308395462 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1306" @default.
- W4308395462 hasPublicationYear "2022" @default.
- W4308395462 type Work @default.
- W4308395462 citedByCount "0" @default.
- W4308395462 crossrefType "proceedings-article" @default.
- W4308395462 hasAuthorship W4308395462A5002443518 @default.
- W4308395462 hasAuthorship W4308395462A5029334249 @default.
- W4308395462 hasAuthorship W4308395462A5029510428 @default.
- W4308395462 hasAuthorship W4308395462A5039840041 @default.
- W4308395462 hasAuthorship W4308395462A5049738219 @default.
- W4308395462 hasAuthorship W4308395462A5056642071 @default.
- W4308395462 hasAuthorship W4308395462A5061180419 @default.
- W4308395462 hasAuthorship W4308395462A5068979537 @default.
- W4308395462 hasAuthorship W4308395462A5071981681 @default.
- W4308395462 hasAuthorship W4308395462A5077537859 @default.
- W4308395462 hasAuthorship W4308395462A5080933448 @default.
- W4308395462 hasBestOaLocation W43083954621 @default.
- W4308395462 hasConcept C126322002 @default.
- W4308395462 hasConcept C137923570 @default.
- W4308395462 hasConcept C203014093 @default.
- W4308395462 hasConcept C2776968632 @default.
- W4308395462 hasConcept C2777165150 @default.
- W4308395462 hasConcept C2777406300 @default.
- W4308395462 hasConcept C2777637488 @default.
- W4308395462 hasConcept C2908647359 @default.
- W4308395462 hasConcept C2911091166 @default.
- W4308395462 hasConcept C2994496256 @default.
- W4308395462 hasConcept C501593827 @default.
- W4308395462 hasConcept C523546767 @default.
- W4308395462 hasConcept C539455810 @default.
- W4308395462 hasConcept C54355233 @default.
- W4308395462 hasConcept C61716771 @default.
- W4308395462 hasConcept C71924100 @default.
- W4308395462 hasConcept C86803240 @default.
- W4308395462 hasConcept C89423630 @default.
- W4308395462 hasConcept C90924648 @default.
- W4308395462 hasConcept C98274493 @default.
- W4308395462 hasConcept C99454951 @default.
- W4308395462 hasConceptScore W4308395462C126322002 @default.
- W4308395462 hasConceptScore W4308395462C137923570 @default.
- W4308395462 hasConceptScore W4308395462C203014093 @default.
- W4308395462 hasConceptScore W4308395462C2776968632 @default.
- W4308395462 hasConceptScore W4308395462C2777165150 @default.
- W4308395462 hasConceptScore W4308395462C2777406300 @default.
- W4308395462 hasConceptScore W4308395462C2777637488 @default.
- W4308395462 hasConceptScore W4308395462C2908647359 @default.
- W4308395462 hasConceptScore W4308395462C2911091166 @default.
- W4308395462 hasConceptScore W4308395462C2994496256 @default.
- W4308395462 hasConceptScore W4308395462C501593827 @default.
- W4308395462 hasConceptScore W4308395462C523546767 @default.
- W4308395462 hasConceptScore W4308395462C539455810 @default.
- W4308395462 hasConceptScore W4308395462C54355233 @default.
- W4308395462 hasConceptScore W4308395462C61716771 @default.
- W4308395462 hasConceptScore W4308395462C71924100 @default.
- W4308395462 hasConceptScore W4308395462C86803240 @default.
- W4308395462 hasConceptScore W4308395462C89423630 @default.
- W4308395462 hasConceptScore W4308395462C90924648 @default.
- W4308395462 hasConceptScore W4308395462C98274493 @default.
- W4308395462 hasConceptScore W4308395462C99454951 @default.
- W4308395462 hasLocation W43083954621 @default.
- W4308395462 hasOpenAccess W4308395462 @default.
- W4308395462 hasPrimaryLocation W43083954621 @default.
- W4308395462 hasRelatedWork W1482883615 @default.
- W4308395462 hasRelatedWork W2103600425 @default.
- W4308395462 hasRelatedWork W2274515720 @default.
- W4308395462 hasRelatedWork W2804959616 @default.
- W4308395462 hasRelatedWork W2984175898 @default.
- W4308395462 hasRelatedWork W3005662382 @default.
- W4308395462 hasRelatedWork W3098440302 @default.
- W4308395462 hasRelatedWork W4223903436 @default.
- W4308395462 hasRelatedWork W4283374890 @default.
- W4308395462 hasRelatedWork W4366603744 @default.
- W4308395462 isParatext "false" @default.
- W4308395462 isRetracted "false" @default.
- W4308395462 workType "article" @default.